Latest 10-Q quarterly reports

Quantum Cyber N.V. (formerly Mainz Biomed N.V.) reported substantial operating losses for Q2 2026, driven by significant R&D investments in its new AI and quantum drone technology focus, alongside the divestiture of its diagnostic testing business.

Genvor Incorporated's Q3 2026 Form 10-Q reveals significant operating losses and a continued lack of revenue, highlighting ongoing concerns about the company's liquidity and ability to continue as a going concern.

Nuvera Communications, Inc. filed its Q2 2026 10-Q, showing revenue growth in data services and improved operating income, despite a net loss for the quarter.

VerifyMe, Inc. announced its second quarter 2026 financial results, revealing a substantial revenue decrease and a widening net loss, while also providing updates on its proposed merger with Open World Ltd. and addressing a Nasdaq delisting notice.

TuHura Biosciences disclosed its Q2 2026 financial results, highlighting increased R&D spending and a substantial net loss, while also detailing a new $50 million credit facility and ongoing efforts to secure additional capital.

Lightwave Logic, Inc. (LWLG) filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased operating expenses and a widening net loss, though revenue saw a modest increase.

PMV Pharmaceuticals reports significant net losses and substantial doubt regarding its ability to continue as a going concern, despite progress in its lead drug candidate, rezatapopt.

LanzaTech Global, Inc. reported a significant net income of $169.6 million for the six months ended June 30, 2026, largely due to a $208.1 million fair value gain on its investment in SGLT, while operational cash outflows decreased.

AirJoule Technologies Corporation filed its Q2 2026 10-Q, reporting a net loss of $8.5 million for the quarter and $58.4 million year-to-date, alongside significant equity investment losses.

First Carolina Financial Services, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting increased net income and diluted EPS, alongside a successful initial public offering.

Galectin Therapeutics reported continued operating losses and substantial doubt regarding its ability to continue as a going concern, despite some positive signals from its NAVIGATE trial subgroup analysis.

HawkEye 360 reports substantial revenue growth and a strong cash position following its IPO, but faces challenges with operational losses and identified material weaknesses in internal controls.

NexPoint Diversified Real Estate Trust filed its Form 10-Q for the quarter ended June 30, 2026, detailing a net income of $2.04 million, a significant improvement from the prior year's net loss, driven by investment gains.

GRI Bio, Inc. (GRI) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development for its lead candidate GRI-0621 and highlighting significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Teamshares Inc. filed its Q2 2026 Form 10-Q, revealing revenue growth driven by acquisitions but highlighting substantial doubt about its ability to continue as a going concern due to significant debt obligations.

Lantern Pharma reported a net loss of $10.4 million for the first six months of 2026, highlighting substantial doubt about its ability to continue as a going concern without significant additional funding.

ZW Data Action Technologies Inc. filed its Q2 2026 Form 10-Q, reporting a decrease in total revenues to $1.04 million for the six months ended June 30, 2026, down from $2.2 million in the prior year period, alongside a net loss of $0.22 million.

Creative Realities Inc. reported a net loss of $3.9 million for Q2 2026, with total sales increasing 65% to $21.5 million, largely driven by the acquisition of Cineplex Digital Media.

Neumora Therapeutics disclosed its Q2 2026 financial results, highlighting reduced operating expenses but also substantial accumulated deficit and ongoing concerns about its ability to continue as a going concern.

Tvardi Therapeutics reported continued operating losses and a substantial accumulated deficit in its Q2 2026 10-Q filing, though it highlighted positive clinical data for its TTI-109 candidate and recent capital raises.

Keemo Fashion Group Limited filed its Q1 2027 Form 10-Q, detailing continued net losses, a significant shareholders' deficit, and material weaknesses in its internal control over financial reporting.

QXO, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing substantial revenue growth driven by recent acquisitions, alongside increased debt and operational expenses.

AleeanPeace Group Holdings Limited (formerly SEATech Ventures Corp.) filed its Form 10-Q for the quarter ended June 30, 2026, reporting no revenue, a continued accumulated deficit, and material weaknesses in internal controls.

Owlet, Inc. announced a significant increase in total revenue for the second quarter of 2026, driven by strong hardware sales and substantial subscription growth, despite continued net losses.

Yubo International Biotech Limited filed its Q2 2026 Form 10-Q, reporting zero revenue for the period and continued net losses, raising substantial doubt about its going concern status.

Rein Therapeutics reports continued net losses and an accumulated deficit, though it has sufficient cash to fund operations into early 2028 and is advancing its LTI-03 Phase 2 trial.

Nevada Canyon Gold Corp. reported a wider net loss for Q2 2026 driven by increased exploration expenses and stock-based compensation, while cash reserves remain sufficient for the next 12 months.

SPACSphere Acquisition Corp. filed its Q2 2026 Form 10-Q, detailing its financial status and progress towards a business combination with Mobilewalla.

Cyngn Inc. has filed an amendment to its Q2 2026 Form 10-Q to include an inadvertently omitted exhibit, specifically an amended and restated offer letter for its CFO, Natalie Russell, which includes a salary increase.

Yinfu Gold Corporation's Q2 2026 10-Q filing reveals no revenue, a growing deficit, and material weaknesses in internal controls, highlighting significant going concern risks.